Patrick Blažek

Patrick Blažek

Auto-generated profile, based on publicly available information

Patrick Blažek

Deutsches Herzzentrum München, Klinik für Herz- und Kreislauferkrankungen, Abteilung für Elektrophysiologie, Faculty of Medicine, Technische Universität München, Munich, Germany

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 March 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
CLCarsten Lennerz
Carsten Lennerz
HVHrvoje Vrazic
Hrvoje Vrazic
BHBernhard Haller
Bernhard Haller
SBSiegmund Braun
Siegmund Braun
TPTobias Petzold
Tobias Petzold
CKChristof Kolb
Christof Kolb
The use of cardiac implantable electronic devices (CIED) has risen steadily, yet the rate of cardiac device infections (CDI) has disproportionately increased. Amongst all cardiac device infections, the pocket infection is the most challenging diagnosis. Therefore, we aimed to improve diagnosis of such pocket infection by identifying relevant biomarkers. We enrolled 25 consecutive patients with invasively and microbiologically confirmed pocket infection. None of the patients had any confounding conditions. Pre-operative levels of 14 biomarkers were compared in infected and control (n = 50) patients. Our selected biomarkers included white blood cell count (WBC), C-reactive protein (CRP), procalcitonin (PCT), lipopolysaccharide binding protein, high-sensitivity C-reactive protein (HS-CRP), polymorphonuclear-elastase, presepsin, various interleukins, tumor necrosis factor α (TNF-α), and granulocyte macrophage colony-stimulating factor (GM-CSF). Of the 25 patients with isolated pocket infection (70±13years, 76% male, 40% ICDs), none presented with leukocytosis. In contrast, they had higher serum levels of HS-CRP (p = 0.019) and PCT (p = 0.010) than control patients. Median PCT-level was 0.06 ng/mL (IQR 0.03–0.07 ng/mL) in the study group versus 0.03 ng/mL (IQR 0.02–0.04 ng/mL) in controls. An optimized PCT cut-off value of 0.05 ng/mL suggests pocket infection with a sensitivity of 60% and specificity of 82%. In addition TNF-α- and GM-CSF-levels were lower in the study group. Other biomarkers did not differ between groups. Diagnosis of isolated pocket infections requires clinical awareness, physical examination, evaluation of blood cultures and echocardiography assessment. Nevertheless, measurement of PCT- and HS-CRP-levels can aid diagnosis. However, no conclusion can be drawn from normal WBC-values. clinicaltrials.gov identifier: NCT01619267

20 November 2018 in Clinical Research in Cardiology
Verified
Journal Article
Closed access
PDF file
VSVerena Semmler
Verena Semmler
FKFelix von Krogh
Felix von Krogh
BHBernhard Haller
Bernhard Haller
TRTilko Reents
Tilko Reents
FBFelix Bourier
Felix Bourier
IDIsabel Deisenhofer
Isabel Deisenhofer

4 September 2018 in Annals of Internal Medicine
Verified
Journal Article
Closed access
PDF file
CLCarsten Lennerz
Carsten Lennerz
MOMatthew O'COnnor
Matthew O'COnnor
LHLorenz Horlbeck
Lorenz Horlbeck
JMJonathan Michel
Jonathan Michel
SWSeverin Weigand
Severin Weigand
CKChristof Kolb
Christof Kolb

13 January 2020 in Technology and Health Care
Verified
Journal Article
Closed access
PDF file
CLCarsten Lennerz
Carsten Lennerz
LHLorenz Horlbeck
Lorenz Horlbeck
SWSeverin Weigand
Severin Weigand
CGChristian Grebmer
Christian Grebmer
PBPatrick Blazek
Patrick Blazek
MOMatthew O’connor
Matthew O’connor
BACKGROUND: Electric cars are increasingly used for public and private transportation and represent possible sources of electromagnetic interference (EMI). Potential implications for patients with cardiac implantable electronic devices (CIED) range f

17 April 2023 in EP Europace
Verified
Journal Article
Open access
PDF file
CLCarsten Lennerz
Carsten Lennerz
CSClaudia Schaarschmidt
Claudia Schaarschmidt
PBPatrick Blažek
Patrick Blažek
KKKatharina Knoll
Katharina Knoll
MKMarc Kottmaier
Marc Kottmaier
MOMatthew O'COnnor
Matthew O'COnnor
Aims: Battery electric vehicle (BEV) sales and use are rapidly expanding. Battery electric vehicles, along with their charging stations, are a potential source of electromagnetic interference (EMI) for patients with cardiac implantable electronic devices (CIEDs). The new ‘high-power’ charging stations have the potential to create strong electromagnetic fields and induce EMI in CIEDs, and their safety has not been evaluated. Methods and results: A total of 130 CIED patients performed 561 charges of four BEVs and a test vehicle (350 kW charge capacity) using high-power charging stations under continuous 6-lead electrocardiogram monitoring. The charging cable was placed directly over the CIED, and devices were programmed to maximize the chance of EMI detection. Cardiac implantable electronic devices were re-interrogated after patients charged all BEVs and the test vehicle for evidence of EMI. There were no incidences of EMI, specifically no over-sensing, pacing inhibition, inappropriate tachycardia detection, mode switching, or spontaneous reprogramming. The risk of EMI on a patient-based analysis is 0/130 [95% confidence interval (CI) 0%–2%], and the risk of EMI on a charge-based analysis is 0/561 (95% CI 0%–0.6%). The effective magnetic field along the charging cable was 38.65 µT and at the charging station was 77.9 µT. Conclusions: The use of electric cars with high-power chargers by patients with cardiac devices appears to be safe with no evidence of clinically relevant EMI. Reasonable caution, by minimizing the time spent in close proximity with the charging cables, is still advised as the occurrence of very rare events cannot be excluded from our results.

20 March 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
PBPatrick Blažek
Patrick Blažek
JFJerko Ferri-Certić
Jerko Ferri-Certić
HVHrvoje Vražić
Hrvoje Vražić
CLCarsten Lennerz
Carsten Lennerz
CGChristian Grebmer
Christian Grebmer
CKChristof Kolb
Christof Kolb
Fixation of the pacemaker leads during pacemaker implantation leads to an increase of cardiac Troponin T (cTnT) that can be interpreted as a sign of minimal myocardial damage. This trial evaluates whether the mechanism type of lead fixation influences the magnitude of cTnT release. Patients having a de-novo cardiac pacemaker implantation or a lead revision were centrally randomized to receive either a ventricular lead with an active (screw) or passive (tine) fixation mechanism. High-sensitive Troponin T (hsTnT) was determined on the day of the procedure beforehand and on the following day. 326 Patients (median age (IQR) 75.0 (69.0–80.0) years, 64% male) from six international centers were randomized to receive ventricular leads with an active (n = 166) or passive (n = 160) fixation mechanism. Median (IQR) hsTnT levels increased by 0.009 (0.004–0.021) ng/ml in the group receiving screw-in ventricular leads and by 0.008 (0.003–0.030) ng/ml in the group receiving tined ventricular leads (n.s.). In conclusion pacemaker implantations are followed by a release of hsTnT. The choice between active or passive fixation ventricular leads does not have a significant influence on the extent of myocardial injury and the magnitude of hsTnT release.